<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00086346</url>
  </required_header>
  <id_info>
    <org_study_id>0468H1-313</org_study_id>
    <nct_id>NCT00086346</nct_id>
  </id_info>
  <brief_title>Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients</brief_title>
  <official_title>A Randomized, Open-Label, Comparative Evaluation of Conversion From Calcineurin Inhibitor Treatment to Sirolimus Treatment Versus Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the sirolimus conversion regimen as compared with
      the calcineurin inhibitor continuation regimen with regards to renal function in stable liver
      transplant subjects.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline Adjusted Mean in Glomerular Filtration Rate (GFR)</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>GFR is an index of kidney function. GFR was calculated using Cockcroft-Gault method. A normal GFR is &gt;90 mL/min, higher values indicate better function. Change=adjusted mean of 12 months minus baseline. Mean adjusted for baseline GFR, with antimetabolite therapy status and hepatitis C status as fixed effects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient and Graft Survival</measure>
    <time_frame>12 months</time_frame>
    <description>Endpoint was a composite assessment of patient and graft survival. Patients categorized as graft survival or graft loss. Graft loss defined as pure graft loss (requiring retransplant) or death (with a functioning graft), if the event occurred in the first 12 months after randomization. Patients with missing graft data were counted as graft losses.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With a Biopsy Confirmed Acute Rejection</measure>
    <time_frame>12 months</time_frame>
    <description>Overall event rate is determined as yes or no.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Serum Creatinine</measure>
    <time_frame>12 months</time_frame>
    <description>Observed mean values for serum creatinine.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">607</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus (Rapamune)</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine or Tacrolimus</intervention_name>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than 13 years (age greater than 18 years as required by some local
             regulations).

          -  Receiving immunosuppressive therapy with calcineurin inhibitors (CI) +/-
             corticosteroids +/- antimetabolite.

          -  6 to 144 months after orthotopic liver transplantation.

          -  Cockcroft-Gault GFR values ≥40 mL/min and ≤90mL/min at screening

        Exclusion Criteria:

          -  History of nonhepatic transplantation

          -  Evidence of systemic infection (sepsis, bacteremia, pneumonia etc).

          -  Known or suspected malignancy &lt; 5 years before random assignment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Italy, decresg@wyeth.com</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Germany, MedInfoDEU@wyeth.com</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Belgium, trials-BEL@wyeth.com</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Czech Republic, WPPGCLI@wyeth.com</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Netherlands, trials-NL@wyeth.com</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Switzerland, med@wyeth.com</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For UK, ukmedinfo@wyeth.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-3285</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642-8410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <zip>14021</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clichy</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leiden</city>
        <zip>2300</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbra</city>
        <zip>3049</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <zip>1069-166</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zürich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2004</study_first_submitted>
  <study_first_submitted_qc>July 1, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2004</study_first_posted>
  <results_first_submitted>July 6, 2009</results_first_submitted>
  <results_first_submitted_qc>July 31, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 7, 2009</results_first_posted>
  <last_update_submitted>April 20, 2010</last_update_submitted>
  <last_update_submitted_qc>April 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Wyeth (Registry Contact: Clinical Trial Registry Specialist)</name_title>
    <organization>Wyeth</organization>
  </responsible_party>
  <keyword>Liver</keyword>
  <keyword>Transplant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited October 2002 to November 2006.</recruitment_details>
      <pre_assignment_details>Patients were screened up to 30 days.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sirolimus (SRL) Conversion</title>
          <description>Sirolimus was administered once daily. A loading dose of sirolimus, 10 to 15 mg, was administered in divided doses on day 1: the first dose was given after collection of the sirolimus trough level and a minimum of 4 hours following the last dose of CNI, and the second dose approximately 12 hours after the first dose. On days 2 through 6, sirolimus was administered in a dose of 3 to 5 mg/day. For the remaining study period, day 7 through month 72, appropriate daily doses of sirolimus were administered to attain the recommended trough concentrations of 8 to 16 ng/mL (using a chromatographic method) or 10 to 20 ng/mL (using an immunoassay).</description>
        </group>
        <group group_id="P2">
          <title>Calcineurin Inhibitors (CNI) Continuation</title>
          <description>Calcineurin Inhibitors administered per local practice to attain target trough levels of 3 to 10 ng/mL (tacrolimus) or 50 to 250 ng/mL (cyclosporin A), respectively.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomization</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="393"/>
                <participants group_id="P2" count="214"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="389"/>
                <participants group_id="P2" count="210"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not receive test article</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Patients Dosed With Test Article</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="389"/>
                <participants group_id="P2" count="210"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="249"/>
                <participants group_id="P2" count="187"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Nonmedical event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sirolimus (SRL) Conversion</title>
          <description>Sirolimus was administered once daily. A loading dose of sirolimus, 10 to 15 mg, was administered in divided doses on day 1: the first dose was given after collection of the sirolimus trough level and a minimum of 4 hours following the last dose of CNI, and the second dose approximately 12 hours after the first dose. On days 2 through 6, sirolimus was administered in a dose of 3 to 5 mg/day. For the remaining study period, day 7 through month 72, appropriate daily doses of sirolimus were administered to attain the recommended trough concentrations of 8 to 16 ng/mL (using a chromatographic method) or 10 to 20 ng/mL (using an immunoassay).</description>
        </group>
        <group group_id="B2">
          <title>Calcineurin Inhibitors (CNI) Continuation</title>
          <description>Calcineurin Inhibitors administered per local practice to attain target trough levels of 3 to 10 ng/mL (tacrolimus) or 50 to 250 ng/mL (cyclosporin A), respectively.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="393"/>
            <count group_id="B2" value="214"/>
            <count group_id="B3" value="607"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.0" lower_limit="23.0" upper_limit="76.0"/>
                    <measurement group_id="B2" value="56.5" lower_limit="21.0" upper_limit="73.0"/>
                    <measurement group_id="B3" value="57.0" lower_limit="21.0" upper_limit="76.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="186.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="271"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="421.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean serum creatinine levels</title>
          <units>μmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122.9" spread="32.3"/>
                    <measurement group_id="B2" value="125.2" spread="31.9"/>
                    <measurement group_id="B3" value="123.7" spread="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Adjusted Mean in Glomerular Filtration Rate (GFR)</title>
        <description>GFR is an index of kidney function. GFR was calculated using Cockcroft-Gault method. A normal GFR is &gt;90 mL/min, higher values indicate better function. Change=adjusted mean of 12 months minus baseline. Mean adjusted for baseline GFR, with antimetabolite therapy status and hepatitis C status as fixed effects.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>The intent to treat population was analyzed and consisted of all patients randomly assigned to treatment. Patients were stratified by hepatitis C status and whether or not they were receiving antimetabolite therapy at time of randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus (SRL) Conversion</title>
            <description>Sirolimus was administered once daily. A loading dose of sirolimus, 10 to 15 mg, was administered in divided doses on day 1: the first dose was given after collection of the sirolimus trough level and a minimum of 4 hours following the last dose of CNI, and the second dose approximately 12 hours after the first dose. On days 2 through 6, sirolimus was administered in a dose of 3 to 5 mg/day. For the remaining study period, day 7 through month 72, appropriate daily doses of sirolimus were administered to attain the recommended trough concentrations of 8 to 16 ng/mL (using a chromatographic method) or 10 to 20 ng/mL (using an immunoassay).</description>
          </group>
          <group group_id="O2">
            <title>Calcineurin Inhibitors (CNI) Continuation</title>
            <description>Calcineurin Inhibitors administered per local practice to attain target trough levels of 3 to 10 ng/mL (tacrolimus) or 50 to 250 ng/mL (cyclosporin A), respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Adjusted Mean in Glomerular Filtration Rate (GFR)</title>
          <description>GFR is an index of kidney function. GFR was calculated using Cockcroft-Gault method. A normal GFR is &gt;90 mL/min, higher values indicate better function. Change=adjusted mean of 12 months minus baseline. Mean adjusted for baseline GFR, with antimetabolite therapy status and hepatitis C status as fixed effects.</description>
          <population>The intent to treat population was analyzed and consisted of all patients randomly assigned to treatment. Patients were stratified by hepatitis C status and whether or not they were receiving antimetabolite therapy at time of randomization.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="393"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.45" spread="1.12"/>
                    <measurement group_id="O2" value="-3.07" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.342</p_value>
            <method>Rank ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With a Biopsy Confirmed Acute Rejection</title>
        <description>Overall event rate is determined as yes or no.</description>
        <time_frame>12 months</time_frame>
        <population>The analysis population is the intent to treat. Any patient whose clinical rejection data was incomplete was designated as an acute rejection in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus (SRL) Conversion</title>
            <description>Sirolimus was administered once daily. A loading dose of sirolimus, 10 to 15 mg, was administered in divided doses on day 1: the first dose was given after collection of the sirolimus trough level and a minimum of 4 hours following the last dose of CNI, and the second dose approximately 12 hours after the first dose. On days 2 through 6, sirolimus was administered in a dose of 3 to 5 mg/day. For the remaining study period, day 7 through month 72, appropriate daily doses of sirolimus were administered to attain the recommended trough concentrations of 8 to 16 ng/mL (using a chromatographic method) or 10 to 20 ng/mL (using an immunoassay).</description>
          </group>
          <group group_id="O2">
            <title>Calcineurin Inhibitors (CNI) Continuation</title>
            <description>Calcineurin Inhibitors administered per local practice to attain target trough levels of 3 to 10 ng/mL (tacrolimus) or 50 to 250 ng/mL (cyclosporin A), respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With a Biopsy Confirmed Acute Rejection</title>
          <description>Overall event rate is determined as yes or no.</description>
          <population>The analysis population is the intent to treat. Any patient whose clinical rejection data was incomplete was designated as an acute rejection in the analysis.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="393"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="347"/>
                    <measurement group_id="O2" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatment groups of percentages of patients with biopsy-confirmed acute rejection.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Serum Creatinine</title>
        <description>Observed mean values for serum creatinine.</description>
        <time_frame>12 months</time_frame>
        <population>On-therapy population; consisted of patients who were still receiving study medication at the defined endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus (SRL) Conversion</title>
            <description>Sirolimus was administered once daily. A loading dose of sirolimus, 10 to 15 mg, was administered in divided doses on day 1: the first dose was given after collection of the sirolimus trough level and a minimum of 4 hours following the last dose of CNI, and the second dose approximately 12 hours after the first dose. On days 2 through 6, sirolimus was administered in a dose of 3 to 5 mg/day. For the remaining study period, day 7 through month 72, appropriate daily doses of sirolimus were administered to attain the recommended trough concentrations of 8 to 16 ng/mL (using a chromatographic method) or 10 to 20 ng/mL (using an immunoassay).</description>
          </group>
          <group group_id="O2">
            <title>Calcineurin Inhibitors (CNI) Continuation</title>
            <description>Calcineurin Inhibitors administered per local practice to attain target trough levels of 3 to 10 ng/mL (tacrolimus) or 50 to 250 ng/mL (cyclosporin A), respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum Creatinine</title>
          <description>Observed mean values for serum creatinine.</description>
          <population>On-therapy population; consisted of patients who were still receiving study medication at the defined endpoint.</population>
          <units>µmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.0" spread="38.9"/>
                    <measurement group_id="O2" value="122.4" spread="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>1 way ANOVA, two sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patient and Graft Survival</title>
        <description>Endpoint was a composite assessment of patient and graft survival. Patients categorized as graft survival or graft loss. Graft loss defined as pure graft loss (requiring retransplant) or death (with a functioning graft), if the event occurred in the first 12 months after randomization. Patients with missing graft data were counted as graft losses.</description>
        <time_frame>12 months</time_frame>
        <population>Intent to treat analysis population with stratification by antimetabolite therapy and hepatitis C status.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus (SRL) Conversion</title>
            <description>Sirolimus was administered once daily. A loading dose of sirolimus, 10 to 15 mg, was administered in divided doses on day 1: the first dose was given after collection of the sirolimus trough level and a minimum of 4 hours following the last dose of CNI, and the second dose approximately 12 hours after the first dose. On days 2 through 6, sirolimus was administered in a dose of 3 to 5 mg/day. For the remaining study period, day 7 through month 72, appropriate daily doses of sirolimus were administered to attain the recommended trough concentrations of 8 to 16 ng/mL (using a chromatographic method) or 10 to 20 ng/mL (using an immunoassay).</description>
          </group>
          <group group_id="O2">
            <title>Calcineurin Inhibitors (CNI) Continuation</title>
            <description>Calcineurin Inhibitors administered per local practice to attain target trough levels of 3 to 10 ng/mL (tacrolimus) or 50 to 250 ng/mL (cyclosporin A), respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient and Graft Survival</title>
          <description>Endpoint was a composite assessment of patient and graft survival. Patients categorized as graft survival or graft loss. Graft loss defined as pure graft loss (requiring retransplant) or death (with a functioning graft), if the event occurred in the first 12 months after randomization. Patients with missing graft data were counted as graft losses.</description>
          <population>Intent to treat analysis population with stratification by antimetabolite therapy and hepatitis C status.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="393"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Graft survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="367"/>
                    <measurement group_id="O2" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Graft loss (total)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Graft loss: Pure (with retransplant)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Graft loss: Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Graft loss: Incomplete data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The a priori criterion for declaring non-inferiority was a lower bound of the 95% confidence interval (CI) having a ≥ 5% difference in graft loss. -5.2 is &lt; 5 % difference.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.2</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
            <estimate_desc>Weighted difference in percentage of graft loss: (CNI% minus SRL%); negative values are favorable to CNI group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sirolimus (SRL) Conversion</title>
          <description>Sirolimus was administered once daily. A loading dose of sirolimus, 10 to 15 mg, was administered in divided doses on day 1: the first dose was given after collection of the sirolimus trough level and a minimum of 4 hours following the last dose of CNI, and the second dose approximately 12 hours after the first dose. On days 2 through 6, sirolimus was administered in a dose of 3 to 5 mg/day. For the remaining study period, day 7 through month 72, appropriate daily doses of sirolimus were administered to attain the recommended trough concentrations of 8 to 16 ng/mL (using a chromatographic method) or 10 to 20 ng/mL (using an immunoassay).</description>
        </group>
        <group group_id="E2">
          <title>Calcineurin Inhibitors (CNI) Continuation</title>
          <description>Calcineurin Inhibitors administered per local practice to attain target trough levels of 3 to 10 ng/mL (tacrolimus) or 50 to 250 ng/mL (cyclosporin A), respectively.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="193"/>
                <counts group_id="E2" subjects_affected="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Aplastic anema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Coagulation disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>International normalized ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Lymphagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Microcytic anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Arterial anomaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>AV block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>AV block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Cerebral ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Coronary occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Left heart failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Myocardial infarct</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Thyroid disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract specified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Eye hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Retinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Carcinoma of the mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Esophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Gamma glutamyl transpeptidase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Ileitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Liver damage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Liver fatty deposit</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Liver function tests abnormal</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Melena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Nausea and vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Peridontal abcess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Rectal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Sclerosing cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Stools abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Ulcerative colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Abdominal syndrome acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Accidental injury</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Diarrhea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Face edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Flu syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Medication error</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Local reaction to procedure</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Surgical procedure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Alkaline phosphotase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Bilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>BUN increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Electrolyte abnormality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Healing abnormal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hyperlipemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Peripheral edema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>SGOT increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>SGPT increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Arthrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Bone necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Musculoskeletal anomaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>CNS neoplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hypesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Subdural hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Albuminuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Kidney calculus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Kidney failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Kidney function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Nephrosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Nephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Uremia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Urinary tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Urine abnormality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Urolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Fallopian tube disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Ovarian disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Prostatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Prostatic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Unintended pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Cough increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Interstitial pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Lung edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Lung hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Lung infiltration nos</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Maculopapular rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Purpuric rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Skin carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Skin hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Skin melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Mesenteric venous occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Postural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pulmonary embolus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="386" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="201" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Liver function tests abnormal</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Accidental injury</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Face edema</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Flu syndrome</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Flu Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Local reaction to procedure</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>BUN increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hypercholesteremia</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hyperlipemia</sub_title>
                <counts group_id="E1" subjects_affected="159" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Lactic dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Peripheral edema</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>SGOT increased</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>SGPT increased</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Leg cramps</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Albuminuria</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Kidney function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough increased</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Skin hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Herpes Simplex</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Skin Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>U. S. Contact Center</name_or_title>
      <organization>Wyeth</organization>
      <email>clintrialresults@wyeth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

